BidaskClub upgraded shares of Assembly Biosciences (NASDAQ:ASMB) from a sell rating to a hold rating in a research report released on Saturday morning.

ASMB has been the subject of a number of other reports. Zacks Investment Research downgraded Assembly Biosciences from a buy rating to a hold rating in a research report on Wednesday, February 20th. Leerink Swann started coverage on Assembly Biosciences in a research note on Monday, November 19th. They set an outperform rating and a $45.00 target price for the company. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $47.00.

Shares of Assembly Biosciences stock opened at $20.23 on Friday. Assembly Biosciences has a one year low of $17.70 and a one year high of $63.15. The stock has a market cap of $516.69 million, a PE ratio of -5.08 and a beta of 1.77.

A number of hedge funds have recently bought and sold shares of ASMB. First Trust Advisors LP purchased a new stake in Assembly Biosciences during the third quarter worth approximately $1,624,000. Wells Fargo & Company MN lifted its stake in Assembly Biosciences by 18.3% during the third quarter. Wells Fargo & Company MN now owns 64,444 shares of the biopharmaceutical company’s stock worth $2,394,000 after purchasing an additional 9,977 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Assembly Biosciences by 3.8% during the third quarter. JPMorgan Chase & Co. now owns 82,769 shares of the biopharmaceutical company’s stock worth $3,074,000 after purchasing an additional 3,022 shares during the last quarter. Swiss National Bank lifted its stake in Assembly Biosciences by 21.9% during the third quarter. Swiss National Bank now owns 35,100 shares of the biopharmaceutical company’s stock worth $1,304,000 after purchasing an additional 6,300 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky purchased a new stake in Assembly Biosciences during the third quarter worth approximately $540,000. Hedge funds and other institutional investors own 83.79% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

Recommended Story: Return On Assets

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.